Intravenous infusion of magnesium sulphate after acute myocardial infarction: effects on arrhythmias and mortality

Smith, L.F.; Heagerty, AM; Bing, Rong; Barnett, D B

doi:10.1016/0167-5273(86)90239-1

Cited by 123 publications

(22 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The antiarrhythmic properties of magnesium were the main reasons for introducing this agent into the treatment of acute myocardial infarction. 6 Experimental data have shown promising results with magnesium in ischemia reperfusion injury, both in reducing infarct size as well as reversing myocardial stunning. 7 The underlying mechanisms are still under discussion, but may include the antithrombotic effects of magnesium preventing microvascular obstruction.…”

Section: Magnesium Biocorrodible Stentmentioning

confidence: 99%

Drug‐Eluting Bioabsorbable Magnesium Stent

Mario¹,

Griffiths²,

Göktekín³

et al. 2004

J Interven Cardiology

399

215

View full text Add to dashboard Cite

Current stent technology is based on the use of permanent implants that remain life long in the vessel wall, far beyond the time required for the prosthesis to accomplish its main goals of sealing dissection and preventing wall recoil. With the possibility to implant long vessel segments using antiproliferative drugs to prevent restenosis, the practice of transforming the coronary vessels into stiff tubes with a full metal jacket covering all side branches and being unable to adjust to the long-term wall changes, including wall remodeling with lumen ectasia becomes a serious concern. In this article, we describe the first biodegradable stent based on a magnesium alloy that allows controlled corrosion with release to the vessel wall and the blood stream of a natural body component such as magnesium with beneficial antithrombotic, antiarrhythmic, and antiproliferative properties. We also discuss the animal experiments and the initial clinical applications in 20 patients with implants below the knee, with final results soon to be released, and the plans for the first coronary study. The results of these last two studies will indicate whether the absence of a permanent implant and the antiproliferative properties shown in animals are sufficient to prevent the restenotic process in humans or whether the prosthesis must be modified by adding the biodegradable coating with conventional antiproliferative drugs.

show abstract

Section: Magnesium Biocorrodible Stentmentioning

confidence: 99%

Drug‐Eluting Bioabsorbable Magnesium Stent

Mario¹,

Griffiths²,

Göktekín³

et al. 2004

J Interven Cardiology

399

215

View full text Add to dashboard Cite

show abstract

“…'67 In addition to previous uncontrolled s t u d i e~,~~J~~ several more recent controlled studies have evaluated the effect of magnesium infusion in the pen-infarction period. [168][169][170][171][172][173] When findings from all studies were analyzed, only 3.8% of the patients in the treated group died, compared with 8.0% of the control…”

Section: Myocardial Infarctionmentioning

confidence: 99%

Magnesium disorders and cardiovascular diseases

Purvis

Movahed

1992

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…Of particular relevance to the present review is the effectiveness of magnesium in preventing arrhythmias arising in acutely ischaemic myocardium. There is empirical evidence for this both from randomized clinical trials in patients with acute myocardial infarction (Abraham et al, 1987;Ceremuzynski et al, 1989;Rasmussen et al, 1987;Schechter et al, 1990;Smith et al, 1986) and from experimental models of myocardial ischaemia (Barros et al, 1988;Crampton & Clark, 1983;Haverkamp et al, 1988). How do arrhythmias develop in acute ischaemia, and how might magnesium inhibit them?…”

Section: Electrophysiological and Antiarrhythmic Effects Of Magnesiummentioning

confidence: 99%

“…Haemodynamic effects Seven randomised clinical trials in a total of over 1,300 patients have examined the effects of intravenous magnesium salts (chloride or sulphate) given early after acute myocardial infarction. Five of them (Abraham et al, 1987;Ceremuzynski et al, 1989;Rasmussen et al, 1986Rasmussen et al, , 1987Rasmussen et al, , 1988aSchechter et al, 1990;Smith et al, 1986) reported a reduction in mortality, in frequency of arrhythmias or both in those patients who received magnesium. Two (Feldstedt et al, 1988;Morton et al, 1984) were negative; the first of these included only 76 patients.…”

Section: Introductionmentioning

confidence: 98%